Bank Of America Reports A 7.4% Passive Stake In Q32 Bio
The bank holds 2,205,390 shares of the Waltham biotech and certifies it has no aim of influencing control.
Bank of America holds 2,205,390 shares of Q32 Bio, a 7.4% stake in the clinical-stage biotech, according to a passive ownership filing made Wednesday. The bank certified the shares were bought in the ordinary course of business, not to change or influence control of the company.
A 7.4% position across three units
The filing puts the event date at September 30, 2026. Bank of America has no sole voting power over the position and shared voting power over 2,204,979 shares.
The bank filed for itself and three wholly owned subsidiaries: BofA Securities, Bank of America N.A. and Merrill Lynch, Pierce, Fenner & Smith.
The 7.4% rests on 29,769,466 shares outstanding, the count Q32 Bio gave in its 10-Q filed August 5, 2026, as of August 3, 2026.
A biotech built around alopecia areata
Q32 Bio develops biologics, drugs made from living cells, aimed at restoring immune balance in alopecia areata, an autoimmune condition that causes hair loss, and other autoimmune and inflammatory diseases. Its lead candidate, bempikibart, blocks two immune-signaling proteins and is in an ongoing Phase 2a trial in alopecia areata, with 33 patients enrolled in Part B, according to its 10-K for 2025.
The company has no approved products. Its revenue comes from collaboration and asset-sale deals, including the November 28, 2025 sale of its ADX-097 program to Akebia Therapeutics.
Shares up 3.44% on the day
Q32 Bio shares rose 3.44% to $9.01 in Wednesday trading, from a prior close of $8.71. That gives the company a market value of $259 million.
The filing is a passive disclosure, and the bank's certification says the stake is not held to influence control of Q32 Bio.
